Gemlapodect_product_DataBase

Bioactivity	Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia[1].
In Vivo	Gemlapodect (5-15 mg；口服；一天一次持续 6 周) 显著改善儿童期发作性流利性障碍 (COFD) 患者的工作和生活社会功能，显示出生物安全性[2]。Gemlapodect (10 mg/kg；口服；单剂量) 在 9 周龄的 SD 大鼠中不改变葡萄糖耐受性。[2]。Gemlapodect (0.3 mg/kg；口服；一天一次持续 8 天) 在 10 周龄的 SD 大鼠中诱导葡萄糖耐受性轻微改善，空腹血糖无变化，空腹胰岛素降低[2]。 Animal Model:
Name	Gemlapodect
CAS	1380329-87-2
Formula	C22H21N7O3
Molar Mass	431.45
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zagorska A, et al. Phosphodiesterase 10 Inhibitors - Novel Perspectives for Psychiatric and Neurodegenerative Drug Discovery. Curr Med Chem. 2018;25(29):3455-3481. [2]. GARIBALDI, et al. METHODS FOR THE TREATMENT OF CHILDHOOD-ONSET FLUENCY DISORDER. World Intellectual Property Organization. WO2022162193

PeptideDB